Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland.
Swiss Med Wkly. 2012 Jul 9;142:w13615. doi: 10.4414/smw.2012.13615. eCollection 2012.
QUESTIONS UNDER STUDY/PRINCIPLES: Data regarding the prevalence and types of drug-related problems (DRPs) among neurology inpatients is sparse. The objective of this study was to characterise the types of DRPs seen among neurology inpatients and furthermore to study factors affecting the acceptance of clinical pharmacologists' and pharmacists' recommendations for improving drug safety.
1,263 consecutive inpatient cases in a Swiss university hospital neurology unit were assessed for the presence of DRPs over 12 months. Treating neurologists' acceptance of the resulting recommendations was also recorded. Primary outcome measures were types of DRP, recommendations made by clinical pharmacologists and number of recommendations accepted. Factors potentially associated with acceptance were studied using univariate and multivariate generalised estimating equation modelling.
Twenty-nine percent of cases demonstrated one or more DRPs. DRPs were the cause of admission in 10 cases (0.8%). In total 494 DRPs were identified and 467 recommendations given, of which 62% were accepted. Factors associated with an increased likelihood of acceptance were prescriptions involving regularly administered drugs (odds ratio [OR] 2.57 95% confidence interval [CI] 1.73-3.80), adverse drug events (OR 2.5; 95% CI 1.29-5.06), known drug side-effect (OR 1.85; 95% CI 1.06-3.22), high-risk drug-drug interactions (OR 3.22; 95% CI 1.07-9.69) and interventions involving changing a drug (OR 2.71; 95% CI 1.17-6.25).
Clinical pharmacologists and pharmacists can play an important role in identifying DRPs among neurology inpatients. Their recommendations for optimising medication-safety are most likely to be accepted for regular prescriptions, prescriptions associated with an adverse drug event and high-risk drug combinations.
研究问题/原则:关于神经科住院患者药物相关问题 (DRP) 的流行率和类型的数据很少。本研究的目的是描述神经科住院患者中出现的 DRP 类型,并进一步研究影响临床药理学家和药剂师提出的改善药物安全性的建议的接受程度的因素。
在瑞士一所大学医院神经内科 12 个月内评估了 1,263 例连续住院患者是否存在 DRP。还记录了治疗神经科医生对由此产生的建议的接受程度。主要观察指标为 DRP 类型、临床药理学家提出的建议和接受的建议数量。使用单变量和多变量广义估计方程模型研究与接受相关的潜在因素。
29%的病例存在一个或多个 DRP。DRP 是 10 例患者(0.8%)入院的原因。共发现 494 例 DRP 和 467 例建议,其中 62%被接受。与接受可能性增加相关的因素包括经常使用药物的处方(优势比 [OR] 2.57,95%置信区间 [CI] 1.73-3.80)、药物不良反应(OR 2.5;95% CI 1.29-5.06)、已知药物副作用(OR 1.85;95% CI 1.06-3.22)、高风险药物相互作用(OR 3.22;95% CI 1.07-9.69)和涉及改变药物的干预措施(OR 2.71;95% CI 1.17-6.25)。
临床药理学家和药剂师可以在识别神经科住院患者中的 DRP 方面发挥重要作用。他们优化药物安全性的建议最有可能被接受,用于常规处方、与药物不良反应相关的处方和高风险药物组合。